Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03047369 · ClinicalTrials.gov registry record

The Myelin Disorders Biorepository Project

A clinical trial of Adrenoleukodystrophy and White Matter Disease, sponsored by Children's Hospital of Philadelphia.

Recruiting
Registry status
12,000
Enrollment target
20
Study locations

NCT03047369 is a study of Adrenoleukodystrophy and White Matter Disease that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 12,000 participants, above the 221-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (5330% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03047369, a study of Adrenoleukodystrophy and White Matter Disease, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.

RECRUITING
Registry status
12,000 participants
Enrollment target
20
Study locations

Study Summary

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Study Locations (20)

California

  • Children's Hospital of Los Angeles - Los Angeles
  • Children's Hospital of Orange County - Orange
  • Stanford University (Lucile Packard Children's Hospital) - Palo Alto
  • University of California, Davis (UC Davis Health) - Sacramento
  • University of California, San Diego (Rady Children's Hospital) - San Diego
  • UCSF Benioff Children's Hospital - San Francisco

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia
  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Minnesota

  • University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

Ohio

  • Akron Children's Hospital - Akron
  • Nationwide Children's Hospital - Columbus

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Emory University (Children's Healthcare of Atlanta) - Atlanta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Maryland

  • Kennedy Krieger Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 12,000 participants
Start Date 2016-12-08
Est. Completion 2030-12-08

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT03047369

The ClinicalTrials.gov registry entry for NCT03047369 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 221-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (5330% higher). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Adrenoleukodystrophy appearing as the primary indexed condition, and to 0 interventions.

NCT03047369 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Pennsylvania, Minnesota.

Frequently Asked Questions

What is clinical trial NCT03047369 about?

NCT03047369 is a clinical study titled "The Myelin Disorders Biorepository Project". The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,...

What is the current status of trial NCT03047369?

This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2016-12-08. Estimated completion is 2030-12-08.

What conditions does trial NCT03047369 study?

This clinical trial studies the following conditions: Adrenoleukodystrophy, White Matter Disease, Leukodystrophy, ALD (Adrenoleukodystrophy), Leukoencephalopathies.

Who is sponsoring clinical trial NCT03047369?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03047369 being conducted?

This trial has 20 study locations across California, District of Columbia, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adrenoleukodystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.